COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Announces $40.0 Million Private Placement
31/03/2026
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases [...]
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious [...]
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease
31/03/2026
March 31, 2026 News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: [...]
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic [...]
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
31/03/2026
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming months, and is [...]
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
31/03/2026
Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic Pancreas IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of [...]
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over [...]
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
31/03/2026
REHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for [...]
Standing Ovation lève $34,2 M pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation, une réponse souveraine et durable à l’explosion de la demande en protéines
31/03/2026
COMMUNIQUÉ DE PRESSE Standing Ovation lève $34,2 millions pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation de précision, une réponse [...]
CancerVax Reports Successful Initial Mouse Study with Breakthrough Results
31/03/2026
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, [...]
SAFE - Forte dynamique de développement au Venezuela
31/03/2026
Forte dynamique de développement au Venezuela Fleurieux-sur-l’Arbresle - France - le 31 mars 2026 à 8h. Après la signature d'un accord de distribution et le succès de la première chirurgie annoncés le 24 avril 2025 , [...]
Transactions in connection with share buy-back program
31/03/2026
Company announcement no. 8 - 26 31 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
31/03/2026
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) -- [...]
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual [...]
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31/03/2026
PRESS RELEASE Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in [...]
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
31/03/2026
Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) [...]
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
31/03/2026
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins [...]
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
31/03/2026
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients [...]
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
31/03/2026
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional [...]

Pages